Copaxone continues to drive Teva in first quarter
This article was originally published in Scrip
Executive Summary
Teva reported strong sales and income growth in the first quarter as it benefited from the ongoing expansion in sales of its multiple sclerosis treatment Copaxone (glatiramer), as well as a solid performance from other generic products and the launch of a generic version of the Parkinson's disease treatment Mirapex (pramipexole) in the US.